CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Artiva Biotherapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Artiva Biotherapeutics Inc
5505 Morehouse Drive
Phone: (858) 267-4467p:858 267-4467 SAN DIEGO, CA  92121  United States Fax: (302) 269-3855f:302 269-3855

Business Summary
Artiva Biotherapeutics, Inc. (Artiva) is advancing a pipeline of off-the-shelf, allogeneic, natural killer (NK) cell-based therapies, for the treatment of hematologic malignancies or solid tumors. The Company's lead product candidate, AB-101, is a non-genetically modified cord blood-derived NK cell therapy that has the potential to enhance the antibody-dependent cell-mediated cytotoxicity (ADCC) response in a cancer patient. In addition, Artiva is developing a portfolio of novel chimeric antigen receptor-NK (CAR-NK) cell product candidates containing chimeric antigen receptors (CARs) that target clinically validated tumor antigens. It's product candidate also includes AB-201 and AB-202. AB-201 is an allogeneic anti-HER2 CAR-NK cell product candidate manufactured from cord blood, containing HER2 antigen recognition domain. The Company's AB-202 is an allogeneic anti-CD19 CAR-NK cell product candidate manufactured from cord blood for the treatment of B-cell malignancies.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-YesYesYes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/202012/31/2020YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
President, Chief Executive Officer FredAslan 1/1/2022 1/1/2022
Co-Founder, Chief Operating Officer PeterFlynn 12/1/2021
Chief Technical Operations Officer ChristopherHoran
Executive Vice President, Chief Legal & People Officer JenniferBush
Vice President - Clinical Operations Michael E.Faerm 51 1/1/2022

General Information
Number of Employees: 25 (As of 3/31/2021)
Outstanding Shares: 3,183,832 (As of 4/8/2021)
Federal Tax Id: 863614316
Fax Number: (302) 269-3855
Email Address: info@artivabio.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, December 19, 2023